Media stories about Vital Therapies (NASDAQ:VTL) have been trending somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vital Therapies earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.5035298170155 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results (finance.yahoo.com)
- Vital Therapies (VTL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS (americanbankingnews.com)
- Vital Therapies, Inc. to Host Earnings Call (baystreet.ca)
- When Will Vital Therapies Inc (NASDAQ:VTL) Breakeven? (finance.yahoo.com)
A number of equities analysts have weighed in on VTL shares. ValuEngine downgraded shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, November 17th. Raymond James Financial reaffirmed a “buy” rating on shares of Vital Therapies in a research note on Tuesday, December 5th. Finally, BidaskClub raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, January 31st.
Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings results on Tuesday, March 13th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.04). During the same period in the prior year, the firm earned ($0.37) EPS. analysts forecast that Vital Therapies will post -1.26 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Vital Therapies (VTL) Earning Somewhat Positive Media Coverage, Accern Reports” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/14/vital-therapies-vtl-earning-somewhat-positive-media-coverage-accern-reports/2028967.html.
About Vital Therapies
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.